NCT06015841Phase 2Active not recruiting

A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease

Study sponsor: AC Immune SA · ACIU

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-06Estimated
Enrollment · participants150Estimated
Source updated2026-10-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, or unlikely, possibly, probably or definitely related) Time frame: From Screening (ICF signature) to Week 100 Measure: Number of participants with abnormal MRI results Time frame: From Baseline to Week 100 Measure: Number of participants with clinically significant changes in physical and neurological examination results Time frame: From Baseline to Week 74 Measure: Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS) Time frame: From Baseline to Week 100 Measure: Measurement of levels of specific antibodies against a-synuclein present in serum generated by ACI-7104.056 Time frame: From Baseline to Week 100. After: Measure: Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, or unlikely, possibly, probably or definitely related) Time frame: From Screening (ICF signature) to Week 100 in study part 1 and 2, and from Rescreening (ICF signature) to Week 78 in the extension phase Measure: Number of participants with abnormal MRI results Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase Measure: Number of participants with clinically significant changes in physical and neurological examination results Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase Measure: Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS) Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase Measure: Measurement of levels of specific antibodies against a-synuclein present in serum generated by ACI-7104.056 Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase.

Primary completion date changed

Before: Jan 2028. After: Jun 2028.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview